Letermovir is under clinical development by Merck & Co and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Letermovir’s likelihood of approval (LoA) and phase transition for Human Immunodeficiency Virus (HIV) Infections (AIDS) took place on 18 Feb 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Letermovir Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Letermovir overview
Letermovir (Prevymis, Privymtra) is a quinazoline derivative acts as an antiviral agent. It is formulated as tablets, film coated tablets for oral route of administration and solution and concentrate solution for intravenous route of administration. Letermovir is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV seropositive recipients [R positive] of an allogeneic hematopoietic stem cell transplant (HSCT).
It is under development for the prevention of human immunodeficiency virus (HIV) infections (AIDS) and HCMV infection in allogeneic hematopoietic stem cell transplant pediatric recipients.
Merck & Co overview
Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
Quick View Letermovir LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|